Non-dilutive funding and resources are available from the National Center for Advancing Translational Sciences (NCATS) to help small businesses and research organizations advance and commercialize promising translational biotech and life sciences research technologies. [HK1] NCATS, a part of the National Institutes of Health, was established to transform the translational science process so that new treatments and cures for disease can be delivered to patients more efficiently. NCATS invites research entrepreneurs to apply for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding.
The SBIR and STTR programs are one of the largest sources of capital for early-stage businesses working towards the commercialization of technologies. These programs can be a vital source of seed funding to help small businesses and research entrepreneurs bring much needed diagnostics, therapeutics, devices, and research tools to market. NCATS supports the development of clinical technologies, instruments, devices, and related methodologies that may have broad application to clinical research and better patient care. There are many benefits to the NCATS SBIR and STTR programs including non-dilutive funding that is not a loan and the ability to retain intellectual property rights.
If you are a researcher interested in bringing your innovations to market, you may be eligible to apply for the NCATS SBIR and STTR programs open funding opportunities. The next deadlines to apply include September 8, 2020, January 5 and April 5, 2021. Learn more about the programs and contact a program director to schedule a time to discuss your research ideas and how to submit a successful application.
Lili Portilla, M.P.A.
NCATS Director of Strategic Alliances